Dec 15, 2022 / 02:00PM GMT
Operator
Good day, and thank you for standing by. Welcome to the cenerimod Phase 3 Initiation Webcast. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Andrew Weiss. Please go ahead.
Andrew C. Weiss - Idorsia Ltd - Senior VP and Head of IR & Corporate Communications
Thank you, operator. Good afternoon, good morning to you all. My name is Andrew Weiss. I'm the Head of Investor Relations and Corporate Communications here at Idorsia. I want to welcome everyone to our webcast to discuss the initiation of the Phase 3 program investigating cenerimod for the treatment of systemic lupus erythematosus, which we announced this morning.
With me on the call here in Allschwil are our Chief Scientific Officer, Martine Clozel; and Alberto Gimona, our Head of Global Clinical Development.
Next slide, please. As customary to these calls, we will be making forward-looking statements. You have therefore been appropriately warned about the risks and
Idorsia Ltd Cenerimod Phase 3 Initiation Webcast Transcript
Dec 15, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers